How can the disclosure risk in data be quantified?
Providing statistical disclosure risk assessments to protect privacy
Challenge
Large data breaches have occurred. These breaches cause growing concern about the mosaic effect in which disparate pieces of information become significant when combined with other types of information on individual privacy.
This escalates disclosure risk by putting personally identifiable information (PII) into the public realm, which makes the mosaic effect very real.
The National Center for Science and Engineering Statistics (NCSES) asked Westat to review its data dissemination products to evaluate their risks.
Solution
Westat conducted a holistic review of NCSES’ data dissemination products relating to disclosure risk.
The review included approaches to risk assessment and quantification using statistical models. Some pieces of the data mosaic were also included in the assessments.
The assessments were accomplished mainly through Westat’s SAS® macros (WesSDC Toolbox) that were developed for statistical confidentiality tasks.
Results
The risk assessments brought to light increased awareness of vulnerabilities.
Westat drafted a standards and guidelines product for statistical confidentiality for the agency.
Various risk mitigation treatments were demonstrated with NCSES survey data, including
- Differential privacy and other noise infusion approaches
- Perturbation and synthetic data applications
Senior Expert Contact
Tom Krenzke
Vice President
-
Expert Interview
Safeguarding Data Privacy: Innovations at WestatOctober 2025
Protecting the privacy of people who respond to surveys and censuses is a critical responsibility in federal data collection. During the 2010 Decennial Census, the…
-
Expert Interview
Novel Strategies Transform Clinical Trials Into Future OpportunitiesOctober 2025
For the rigorous evaluation of novel medicines, clinical trials are essential to ensure safety and efficacy. However, clinical trials are experiencing turbulent times due to…
-
Expert Interview
Real-World Insights: Nirsevimab’s Protection Against RSV in InfantsSeptember 2025
Each year in the U.S., respiratory syncytial virus, commonly known as RSV, leads to approximately 58,000 to 80,000 hospitalizations among children under age 5. The…